Emtricitabine 200mg capsules
Requires a prescription from a doctor or prescriber
Antiretroviral drug used to treat HIV infection
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Emtricitabine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Emtricitabine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Emtricitabine on the MHRA register
Emtriva 200mg capsules
WHO defined daily dose (DDD)
200 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Cabotegravir with rilpivirine for treating HIV-1 (TA757)
Cabotegravir for preventing HIV-1 in adults and young people (TA1106)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Randomised trials: 10 · 2016–2026
Showing all 30 studies, sorted by most relevant.
Kenneth H. Mayer, J. Molina, Melanie Thompson, et al.
Lancet (London, England), 2020
- Emtricitabine
- Tenofovir
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
J. Gallant, A. Lazzarin, A. Mills, et al.
Lancet, 2017
- Emtricitabine
- Tenofovir
- Dolutegravir
P. Sax, A. Pozniak, Luisa Montes, et al.
Lancet, 2017
- Emtricitabine
- Tenofovir
- Dolutegravir
W. Venter, Simiso M Sokhela, Bryony Simmons, et al.
The lancet. HIV, 2020
- Emtricitabine
- Tenofovir
- Duration of Therapy
D. Wohl, Y. Yazdanpanah, A. Baumgarten, et al.
The lancet. HIV, 2019
- Tenofovir
- Dolutegravir
- Abacavir
H. Stellbrink, J. Arribas, J. L. Stephens, et al.
The lancet. HIV, 2019
A. Avihingsanon, Hongzhou Lu, C. L. Leong, et al.
The lancet. HIV, 2023
- Hepatitis B
- Emtricitabine
- Tenofovir
O. Ogbuagu, P. Ruane, D. Podzamczer, et al.
The lancet. HIV, 2021
- Emtricitabine
- Tenofovir
- Adenine
Lola Falcón-Neyra, C. Palladino, M. N. Navarro Gómez, et al.
Medicine, 2016
- Emtricitabine
- Tenofovir
- RNA, Viral
To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initiation of therapy with RPV/FTC/TDF before the age of 18. Patients were divided into undetectable viral load (uVL) group, HIV-1 RNA < 20 copies/mL on stable combined antiretroviral therapy (cART), and detectable viral load (dVL) group, HIV-1 RNA ≥ 20 copies/mL at RPV/FTC/TDF initiation. Patients were monitored from the date of RPV/FTC/TDF initiation until June 30, 2015, RPV/FTC/TDF discontinuation or failure to follow-up. Seventeen patients (8 in uVL and 9 in dVL group) with age between 11.6 and 17.6 were included. Reasons for switching were toxicity (n = 4) and simplification (n = 4) in uVL; viral failure (n = 8) and cART initiation (n = 1) in the dVL group. After a median follow-up of 90 (uVL) and 40 weeks (dVL), 7/8 (86%) patients maintained and 8/9 (89%) achieved and maintained HIV-1 suppression. Median CD4 count increased from 542 to 780/μL (uVL, P = 0.069) and 480 to 830/μL (dVL, P = 0.051). Five patients (2 in uVL and 3 in dVL) improved their immunological status from moderate to no immunosuppression. Serum lipid profiles improved in both groups; cholesterol dropped significantly in the dVL group (P = 0.008). Grade 1 laboratory adverse events (AEs) were observed in 3 patients. No clinical AEs occurred. Adherence was complete in 9 patients (5 in uVL and 4 in dVL); 1 adolescent interrupted treatment. Once-daily STR with RPV/FTC/TDF may be a safe and effective choice in selected HIV-1-infected adolescents and children.
Abstract licence: CC BY
P. Cahn, J. S. Madero, J. Arribas, et al.
Lancet, 2019
- Emtricitabine
- Tenofovir
- Dolutegravir
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
10 hours
Mechanism
Emtricitabine is a cytidine analog which, when phosphorylated to emtricitabine 5…
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.7µg/mL
[L9019]…
Half-life
10 hours
[L9019]
Protein binding
4%
[A19948]
Volume of distribution
42.3L
[A187673]
Metabolism
86%
[L9019]
Approximately 9% of a dose is metabolized to 3'-sulfoxide diastereomers, 4% to the…
Elimination
86%
[L9019]…
Clearance
15.1L/h
[A187673]
This rate is closely linked to creatinine clearance.
[A187673]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Emtricitabine was granted FDA approval on 2 July 2003.[L9019]
[L9019][L9587][L9836][L9833][L9839][L9842][L9647][L9845][L9848][L44226][L50522][L53758]
As different products of emtricitabine are approved for use in patients with certain characteristics, refer to the individual drug product for patient eligibility for drug treatment. It may be used for pre-exposure prophylaxis of HIV-1 in adolescents and adults.
[L4388][L9010]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 61 interactions
Symptoms of emtricitabine toxicity include hepatotoxicity with steatosis, as well as lactic acidosis.
[L9019]
Treat overdose with symptomatic and supportive measures, including hemodialysis.
[L9019]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L9019]
The bioavailability of emtricitabine capsules is 93% and the bioavailability of the oral solution is 75%.
[L9019]
Taking emtricitabine with food decreases the Cmax by 29%.[L9019
[L9019]
[A19948]
[A187673]
[L9019]
Approximately 9% of a dose is metabolized to 3'-sulfoxide diastereomers, 4% to the 2'-O-glucuronide, and a minor amount is converted to 5-fluorocytosine.
[A187643][L9019]
[L9019]
13% of the dose is recovered in the urine as metabolites; 9% as 3'-sulfoxide diastereomers and 4% as 2'-O-glucuronide.
[L9019]
[A187673]
This rate is closely linked to creatinine clearance.
[A187673]
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:16330770 PMID:17509534
Plays a physiological role in the excretion of cationic compounds including endogenous metabolites, drugs, toxins through the kidney and liver, into urine and bile respectively .
PMID:16330770 PMID:17495125 PMID:17509534 PMID:17582384 PMID:18305230 PMID:19158817 PMID:21128598 PMID:24961373
Mediates the efflux of endogenous compounds such as creatinine, vitamin B1/thiamine, agmatine and estrone-3-sulfate .
PMID:16330770 PMID:17495125 PMID:17509534 PMID:17582384 PMID:18305230 PMID:19158817 PMID:21128598 PMID:24961373
May also contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier (Probable)
Proteins that carry this drug through the body
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
ATC J05AR29
ATC J05AR19
ATC J05AR08
ATC J05AR17
ATC J05AF09
ATC J05AR09
ATC J05AR20
ATC J05AR06
ATC J05AR03
ATC J05AR22
ATC J05AR18
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Emtricitabine
Additional database identifiers
Drugs Product Database (DPD)
16516
ChemSpider
54859
BindingDB
50107843
PDB
ETV
ZINC
ZINC000003629271
GenBank Gene Database
U28646
GenBank Protein Database
896047
UniProt Accession
Q72547_HV1
GenBank Gene Database
M15654
GenBank Protein Database
326388
UniProt Accession
POL_HV1B1
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2704
GenAtlas
DCK
GeneCards
DCK
GenBank Gene Database
M60527
UniProt Accession
DCK_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:25588
GeneCards
SLC47A1
GenBank Gene Database
AK001709
GenBank Protein Database
7023138
Guide to Pharmacology
1216
UniProt Accession
S47A1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q422604), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.